Recombinant human erythropoietin β: The effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients

Simple item page
dc.contributor.buuauthorDurmaz, Oǧuzhan
dc.contributor.buuauthorDemirkaya, Metin
dc.contributor.buuauthorSevinir, Betül Berrin
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Pediatri Anabilim Dalı.tr_TR
dc.contributor.researcheridAAH-1570-2021tr_TR
dc.contributor.scopusid14025426300tr_TR
dc.contributor.scopusid24331130000tr_TR
dc.contributor.scopusid6603199915tr_TR
dc.date.accessioned2022-01-06T12:47:32Z
dc.date.available2022-01-06T12:47:32Z
dc.date.issued2011-09
dc.description.abstractAnemia, which is a common problem in cancer patients, has a negative effect on survival by decreasing the efficacy of chemotherapy and particularly of radiotherapy, as well as impairing the quality of life (QoL) of patients. Recombinant human erythropoietin (rHuEPO) decreases a patient's need for transfusions and increases their QoL. The aim of this study was to evaluate the effect of weekly single-dose EPO treatment on transfusion rates, QoL, and hemoglobin (Hb) levels. In addition, patients were followed up for a long period to assess the impact of EPO treatment on survival. The study was conducted from December 2001 to December 2002 in patients with newly diagnosed lymphoma or solid tumors using a prospective and controlled design. EPO-beta was given as a single dose of 450 U/kg once a week for 12 weeks. The study and control groups included 16 patients each. Hb levels measured in the study group at the 4th, 8th, and 12th weeks were significantly higher than the values recorded before the start of chemotherapy. In the control group, Hb levels post chemotherapy were significantly lower than values recorded prior to treatment. The increased Hb levels in the study group were significant at the 8th and 12th weeks of treatment compared to levels measured prior to treatment. In the control group, Hb levels at the 4th and 8th weeks were significantly lower than pretreatment levels. When the percent increase of Hb levels of the study and control groups with respect to treatment week was compared, the difference was statistically significant at the 4th, 8th, and 12th weeks. Although the increase on the performance scale within each group during treatment was significant in both the study and control groups, the increase was more marked in the study group. The percent increase on the performance scale with respect to week of treatment was higher in the study group than in the control group. In EPO treatment group, side effects were seen in 38% of patients, with 19% being local pain in the injection area, 13% local hyperemia, and 6% headache. The mean follow-up period of the study and control group was 7.03 +/- 0.41 (6.0-7.41) and 7.46 +/- 0.45 (6.58-7.83) years, respectively; no statistically significant difference existed between these figures. Overall survival at the end of 7 years of follow-up was 68.8% and 81.3% for the study and control groups, respectively. The use of EPO-beta in lymphoma and solid tumor patients on a once-weekly regimen (450 U/kg) was determined to be effective in increasing Hb levels, decreasing transfusion rates, and improving QoL. This regimen was safe, did not cause serious side effects, and can be recommended because of its high patient compliance and tolerability. An effect of EPO on prognosis was not evident. We could not have an explanation on the effect of EPO treatment on prognosis, as there were low number of patients and advanced-staged patients died earlier. Therefore, a larger number of patients are needed to clarify the effect of EPO treatment on prognosis.en_US
dc.identifier.citationDurmaz, O. vd. (2011). "Recombinant human erythropoietin β: The effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients". Pediatric Hematology and Oncology, 28(6), 461-468.en_US
dc.identifier.endpage468tr_TR
dc.identifier.issn0888-0018
dc.identifier.issue6tr_TR
dc.identifier.pubmed21707225tr_TR
dc.identifier.scopus2-s2.0-80051966164tr_TR
dc.identifier.startpage461tr_TR
dc.identifier.urihttps://doi.org/10.3109/08880018.2011.570857
dc.identifier.urihttps://www.tandfonline.com/doi/full/10.3109/08880018.2011.570857
dc.identifier.urihttp://hdl.handle.net/11452/23911
dc.identifier.volume28tr_TR
dc.identifier.wos000294065900002tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherTaylor & Francisen_US
dc.relation.journalPediatric Hematology and Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectOncologyen_US
dc.subjectHematologyen_US
dc.subjectPediatricsen_US
dc.subjectAnemiaen_US
dc.subjectErythropoietinen_US
dc.subjectQuality of lifeen_US
dc.subjectSurvivalen_US
dc.subjectChemotherapy-related anemiaen_US
dc.subjectEpoetin alpha treatmenten_US
dc.subjectStimulating agentsen_US
dc.subjectSolid Tumorsen_US
dc.subjectChildrenen_US
dc.subjectMetaanalysisen_US
dc.subjectDarbepoetinen_US
dc.subject.emtreeHemoglobinen_US
dc.subject.emtreeRecombinant erythropoietinen_US
dc.subject.emtreeRecombinant erythropoietin betaen_US
dc.subject.emtreeUnclassified drugen_US
dc.subject.emtreeAdolescenten_US
dc.subject.emtreeAnemiaen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeCancer growthen_US
dc.subject.emtreeCancer patienten_US
dc.subject.emtreeCancer recurrenceen_US
dc.subject.emtreeCancer survivalen_US
dc.subject.emtreeChilden_US
dc.subject.emtreeClinical articleen_US
dc.subject.emtreeClinical protocolen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDrug tolerabilityen_US
dc.subject.emtreeDrug effecten_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeFollow upen_US
dc.subject.emtreeHeadacheen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeHyperemiaen_US
dc.subject.emtreeInjection site painen_US
dc.subject.emtreeLymphomaen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeOutcome assessmenten_US
dc.subject.emtreeOverall survivalen_US
dc.subject.emtreePreschool childen_US
dc.subject.emtreeQuality of lifeen_US
dc.subject.emtreeSchool childen_US
dc.subject.emtreeSingle drug doseen_US
dc.subject.emtreeSolid tumoren_US
dc.subject.emtreeTreatment outcomeen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAnemiaen_US
dc.subject.meshBlood transfusionen_US
dc.subject.meshChilden_US
dc.subject.meshChild, preschoolen_US
dc.subject.meshDisease-free survivalen_US
dc.subject.meshErythropoietinen_US
dc.subject.meshFollow-up studiesen_US
dc.subject.meshHemoglobinsen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshNeoplasmsen_US
dc.subject.meshProspective studiesen_US
dc.subject.meshQuality of lifeen_US
dc.subject.meshRecombinant proteinsen_US
dc.subject.meshSurvival rateen_US
dc.subject.meshTime factorsen_US
dc.subject.scopusErythropoietin Receptors; Antianemic Agent; Anemiasen_US
dc.subject.wosOncologyen_US
dc.subject.wosHematologyen_US
dc.subject.wosPediatricsen_US
dc.titleRecombinant human erythropoietin β: The effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patientsen_US
dc.typeArticle
dc.wos.quartileQ4en_US
dc.wos.quartileQ3 (Pediatrics)en_US

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus